Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Rutkowski, P.

Refine Results

Resource Type

Availability

Creation Date

Show more

Author

Show more

Language

Search results

  • RSS Feed
(61 - 80 of 87)

Pages

Etoposide and Carbo-or Cisplatin Combination Therapy in Refractory or Relapsed Ewing Sarcoma: A Large Retrospective Study
Building a global consensus approach to chordoma: a position paper from the medical and patient community
Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials
IDENTIFYING BIOLOGICAL AND CLINICAL CHARACTERISTICS OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) RESPONDING TO IMATINIB THERAPY FOR MORE THAN 5 AND 10 YEARS
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatment-use (TU) trial
Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics
Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes
Results from a phase III trial (GRID) evaluating regorafenib in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics
Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib vs placebo in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes
An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours
Time course of adverse events in the phase III GRID study of regorafenib in patients with metastatic gastrointestinal stromal tumors (GIST)
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study
Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REC) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes
Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST) Subgroup analysis of outcomes based on pretreatment characteristics
Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs placebo in TKI-refractory metastatic GIST
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Pages